Publications by authors named "T Tim Bognar"

Claim this Profile
T
Therapeutic Drug Monitoring Versus Fixed-Interval Dosing of Dalbavancin in Implant-Associated Spinal Infections: Grand Round/A Case Study.
Jeroen P A Houwen, Charlotte S Hakkers, Valentijn A Schweitzer, Tim Bognàr, Martha L Toren-Wielema

Ther Drug Monit· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-Informed Precision Dosing of Busulfan for Children and Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Critical Evaluation of Current PK Models and Dose Recommendations.
Rashudy F Mahomedradja, Tim Bognàr, Kaj E van Schie, Ilse T Kuipers, Moniek A de Witte

Clin Pharmacol Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing Allogeneic Hematopoietic Cell Transplantation Outcomes Through Busulfan PK/PD.
Imke H Bartelink, Arief Lalmohamed, Tim Bognar, Erfan Nur, Jaap Jan Boelens

Transplant Cell Ther· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of standard fludarabine dosing and corresponding exposures in infants and young children undergoing hematopoietic cell transplantation.
Julia Möhlmann, Lisanne van der Ploeg, Jurgen Langenhorst, Tim Bognàr, Kim van der Elst

Bone Marrow Transplant· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of busulfan exposure and outcomes after HCT for patients with an inborn error of immunity.
Tim Bognàr, Moises Garcia-Rosa, Arief Lalmohamed, Tayfun Güngör, Mathias Hauri-Hohl

Blood Adv· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis